

WHO und EMA melden mutmaßliche Nebenwirkungen in noch nie dagewesener Zahl und Vielfalt. EMA listet für Biontech allein 970 Verdachtsfälle "death" und 336 "sudden death". Die Dunkelziffer der nicht gemeldeten Fälle liegt lt. EMA bei 97%. Das ist aussagekräftig genug.

Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **TOZINAMERAN** (up to 12/06/2021)

Reaction Groups & Reported Suspected Reaction

Reaction Groups
 General disorders and administration site conditions

Reported Suspected Reaction

- Application site joint inflammation
- Application site joint movement impairment
- Application site joint pain
- Application site joint swelling
- Application site joint warmth
- Application site lymphadenopathy
- Application site mass
- Application site movement impairment
- Application site nerve damage
- Application site nodule
- Application site oedema
- Application site pain
- Application site papules
- Application site paraesthesia
- Application site plaque
- Application site pruritus
- Application site purpura
- Application site rash
- Application site reaction
- Application site swelling
- Application site urticaria
- Application site vesicles
- Application site warmth
- Asthenia
- Atrophy
- Axillary pain
- Brain death
- Breakthrough pain
- Calcinosis
- Capsular contracture associated with breast implant
- Capsular contracture associated with implant
- Cardiac death
- Challenge site reaction
- Chest discomfort
- Chest pain
- Chills
- Chronic fatigue syndrome
- Complication associated with device
- Concomitant disease aggravated
- Concomitant disease progression
- Condition aggravated
- Crepitations
- Critical illness
- Crying
- Cyst
- Death



Choose a Reaction Group and then a Reported Suspected Reaction to see the number of individual cases identified in EudraVigilance for **TOZINAMERAN** (up to 12/06/2021)

Reaction Groups & Reported Suspected Reaction

Reaction Groups
 General disorders and administration site conditions

Reported Suspected Reaction

- Oedema mucosal
- Oedema peripheral
- Oral administration complication
- Organ failure
- Pain
- Pelvic mass
- Perforation
- Performance status decreased
- Peripheral swelling
- Physical deconditioning
- Polyp
- Polyserositis
- Potentiating drug interaction
- Pre-existing condition improved
- Pre-existing disease
- Product intolerance
- Pseudoallergic reaction
- Pseudohermia
- Puncture site bruise
- Puncture site discharge
- Puncture site erythema
- Puncture site haematoma
- Puncture site haemorrhage
- Puncture site hypoaesthesia
- Puncture site induration
- Puncture site oedema
- Puncture site pain
- Puncture site pruritus
- Puncture site reaction
- Puncture site swelling
- Pyrexia
- Reactogenicity event
- Rebound effect
- Screaming
- Secretion discharge
- Sensation of blood flow
- Sensation of foreign body
- Sense of oppression
- Sensitivity to weather change
- Serositis
- Shoulder injury related to vaccine administration
- Sluggishness
- Soft tissue inflammation
- Stenosis
- Sudden cardiac death
- Sudden death

